Informa buys Dove Medical Press in deal of undisclosed value
Events and publishing company Informa announced the acquisition of Dove Medical Press on Tuesday, in a deal with undisclosed financial information.
FTSE 100
8,106.88
10:05 26/04/24
FTSE 350
4,454.04
10:05 26/04/24
FTSE All-Share
4,407.57
10:05 26/04/24
Informa
796.80p
10:04 26/04/24
Media
11,764.58
10:05 26/04/24
The FTSE 100 firm said the addition of an independent open access (OA) publisher increased its “position and capability” in the growing OA market.
It also said the collection of established and indexed journals included in the purchase took Informa’s OA journal portfolio to more than 200, with the total number of journals to over 2,800.
Dove also came with an established platform to identify new subject categories, managing collaboration and peer review, Informa said, with the purchase specifically strengthening its position in the health sciences - particularly in “growth subjects” such as oncology, ophthalmology, neuroscience and psychiatry.
“The addition of Dove Medical Press adds strength and capability to our OA portfolio, further increasing choice and flexibility for researchers across a widening range of subject areas,” said Informa group chief executive Stephen A. Carter.
“Its track record, publishing platform and growing reputation in Health Sciences enhance our Journals business, strengthening our position in the attractive and growing OA market.”
The board of Informa said financial details weren't disclosed, but the transaction was expected to be “modestly accretive” to adjusted earnings in the first full year of ownership, and deliver a return on investment ahead of the cost of capital within three years.